Drug Information
| Drug General Information | |||||
|---|---|---|---|---|---|
| Drug ID |
D0E9JR
|
||||
| Former ID |
DNC009409
|
||||
| Drug Name |
Ethyl 2-cyano-2-(quinoxalin-2(1H)-ylidene)acetate
|
||||
| Drug Type |
Small molecular drug
|
||||
| Indication | Discovery agent | Investigative | [1] | ||
| Structure |
|
Download2D MOL |
|||
| Formula |
C13H11N3O2
|
||||
| Canonical SMILES |
CCOC(=O)C(=C1C=NC2=CC=CC=C2N1)C#N
|
||||
| InChI |
1S/C13H11N3O2/c1-2-18-13(17)9(7-14)12-8-15-10-5-3-4-6-11(10)16-12/h3-6,8,16H,2H2,1H3/b12-9-
|
||||
| InChIKey |
XEXZOINHSIFHFY-XFXZXTDPSA-N
|
||||
| PubChem Compound ID | |||||
| Target and Pathway | |||||
| Target(s) | Collagenase 3 | Target Info | Inhibitor | [1] | |
| NetPath Pathway | IL1 Signaling Pathway | ||||
| PANTHER Pathway | Alzheimer disease-presenilin pathway | ||||
| Plasminogen activating cascade | |||||
| Pathway Interaction Database | Urokinase-type plasminogen activator (uPA) and uPAR-mediated signaling | ||||
| Reactome | Collagen degradation | ||||
| Degradation of the extracellular matrix | |||||
| Activation of Matrix Metalloproteinases | |||||
| Assembly of collagen fibrils and other multimeric structures | |||||
| WikiPathways | Endochondral Ossification | ||||
| Activation of Matrix Metalloproteinases | |||||
| Oncostatin M Signaling Pathway | |||||
| AGE/RAGE pathway | |||||
| Matrix Metalloproteinases | |||||
| References | |||||
| REF 1 | Bioorg Med Chem. 2009 Feb 1;17(3):990-1005. Epub 2008 Mar 6.High throughput screening of potentially selective MMP-13 exosite inhibitors utilizing a triple-helical FRET substrate. | ||||
If You Find Any Error in Data or Bug in Web Service, Please Kindly Report It to Dr. Zhou and Dr. Zhang.